hrp0095p2-176 | Growth and Syndromes | ESPE2022

A case of 1q21 recurrent microdeletion syndrome with growth hormone deficiency, facial dysmorphism, and microcephaly

A Kim Hyun , Kim Jinsup , Ju Lee Hyun , Yang Aram

1q21.1 recurrent microdeletion syndrome is a rare chromosomal disorder caused by a genetic abnormality of non-allelic homologous recombination in the sequence of flanking a copy number variation event during meiosis. The characteristic features of 1q21 microdeletion syndrome are dysmorphic facial appearances with microcephaly, and mild to moderate developmental delay of speech and motor, eye abnormality, short stature, skeletal malformation, and psychiatric and behavioral diso...

hrp0092p1-83 | GH and IGFs | ESPE2019

Identification of Novel Recessive IGFALS Mutations and INSR Variant in an Obese Korean Boy

Kim Yoo-Mi , Lim Han Hyuk , Kim Seon Young

IGFALSgene is located in chromosome 16p13.3 encoding acid labile subunit which binds insulin-like growth factors (IGFs) to increase their half-life and vascular localization. The biallelic defect of this gene leads to acid-labile subunit deficiency characterized by postnatal growth retardation, insulin resistance, delayed puberty, and no growth hormone deficiency. A 5-year-old-boy was referred to as low IGF-1 and cortisol level. He presented with obesity and growth re...

hrp0092p3-156 | Growth and Syndromes (to include Turner Syndrome) | ESPE2019

Growth Status of Children and Adolescent Born Full Term Small-for-Gestational-Age in Korea: Data from the KNHANES-V (2010–2011)

Kim Ji Hyun , Kim Dong Ho , Lim Jung Sub

Background: Currently, little information is available on current growth status according to birth weight at gestational age (BWGA) on Korean adolescents. Herein, the current height and weight of Korean adolescents who were born as small for gestational age (SGA) were compared to those of the non-SGA groups.Methods: Data from the population-based nationwide Korean survey 5th Korea National Health and Nutrition Examinatio...

hrp0086p1-p819 | Syndromes: Mechanisms and Management P1 | ESPE2016

Clinical and Molecular Characterization of a Newly Recognized Overgrowth Syndrome: Interstitial 7q22.1-7q22.3 Microdeletion

Cheon Chong Kun , Kim Yoo-Mi , Kim Su Young

Background: Overgrowth syndromes comprise a group of disorders associated with excessive growth and other features such as facial dysmorphism, developmental delay, neurological problems and an increased risk of neoplasia. The genetic basis for many of these conditions is being increasingly elucidated. Here, we report on a 3-year-old boy who was referred for evaluation of generalized overgrowth.Objective and hypotheses: Our hypotheses is that unclassified...

hrp0082p2-d2-304 | Bone (1) | ESPE2014

Age-and Gender-Specific Reference Values of Bone Mineral Density in Korean Adolescents and Young Adults

Hye Kim Shin , Jung Park Mi , Hee Kim Duk

Background: Low bone mass during growth may increase risk of fracture. Adequate reference data for bone mineral density (BMD) are needed to identify adolescents with bone deficit.Objective and hypotheses: We aimed to provide normative values and reference curves for BMD in Korean adolescents and young adults.Method: Using the data from Korean Nutrition Health and Nutrition Examination Survey (KNHANES) in 2008–2011, a total of ...

hrp0082p2-d2-551 | Puberty and Neuroendocrinology (1) | ESPE2014

The Effect of Combined GH and GnRH Agonist Treatment for Near-Final Height Improvement in True Precocious Puberty and Early Puberty

Kim Se Young , Kim Eun Young , Yi Kyung Hee

Purpose: The goal of treatment for true precocious puberty (TPP) and early puberty with GnRH agonist (GnRHa) is to prevent loss of genetic potential of target height (TH). And to regress secondary sex characteristics appropriate for patient’s age. But some patient’s growth velocity (GV) after treatment would decline and suggest that final height (FH) was not improved. So, we investigated the effect of combined GH and GnRHa treatment for near-FH (NFH) improvement....

hrp0084p1-54 | Diabetes | ESPE2015

‘BestPWS EU’: A Phase 3 Study in Adolescent and Adult Patients With PWS in Europe

Tauber Maithe , Kim Terri , Kreher Nerissa , Kim Dennis , Hauffa Berthold

Background: Prader–Willi Syndrome (PWS) is a complex genetic disease; one hallmark of the disease is failure to regulate hunger and metabolism. Hyperphagia and severe obesity contribute significantly to the morbidity and mortality of this disease. Methionine aminopeptidase 2 (MetAP2) inhibition reduces fat biosynthesis and stimulates fat oxidation and lipolysis. Beloranib is a selective and potent MetAP2 inhibitor. In a 4-week phase 2, placebo-controlled, proof-of-concept...

hrp0084p2-531 | Puberty | ESPE2015

Regional Brain Volume and Luteinising Hormone in Girls with Idiopathic Central Precocious Puberty

Kim Eun Young , Park Shin Eui , Kim Min Sun

Background: During puberty, gray matter (GM) volume decreases and white matter (WM) volume increases in brain. It has been suggested that pubertal hormones may induce some neuroanatomical changes during puberty. Central precocious puberty (CPP) is caused by premature activation of the hypothalamus-pituitary-gonadal axis in inappropriately early age. However, little is known about the differences of brain structure (especially brain volume) in idiopathic CPP. Also the relation ...

hrp0084p3-851 | Fat | ESPE2015

Genotype and Clinical Characteristics in Korean Patients with Prader-Willi Syndrome: A Single Centre Study

Kim Yoo-Mi , Cheon Chong Kun , Kim Su Young

Background: Prader–Willi syndrome (PWS) is characterised by neonatal hypotonia, hypogonadism, progressive obesity, short stature, and mental retardation. This syndrome arises from a loss of expression of paternally derived genes on chromosome 15q11–13 region.Objective and hypotheses: The aim of this study was to investigate clinical characteristics and their genotypes in Korean patients with PWS.Method: The study included...